Microbix Biosystems (TSE:MBX) Director Purchases C$32,200.00 in Stock

Microbix Biosystems Inc. (TSE:MBX – Get Free Report) Director Martin Marino acquired 115,000 shares of the business’s stock in a transaction that occurred on Thursday, May 28th. The stock was acquired at an average cost of C$0.28 per share, with a total value of C$32,200.00. Following the completion of the acquisition, the director owned 2,000,167 shares in the company, valued at C$560,046.76. This trade represents a 6.10% increase in their position.

Martin Marino also recently made the following trade(s):

Get Microbix Biosystems alerts:

• On Tuesday, May 26th, Martin Marino acquired 69,000 shares of Microbix Biosystems stock. The stock was acquired at an average cost of C$0.26 per share, with a total value of C$17,940.00.
• On Wednesday, May 27th, Martin Marino acquired 24,500 shares of Microbix Biosystems stock. The stock was acquired at an average cost of C$0.26 per share, with a total value of C$6,370.00.

Microbix Biosystems Stock Down 1.8%

MBX opened at C$0.27 on Friday. The company has a 50 day moving average of C$0.24 and a 200 day moving average of C$0.24. The company has a market cap of C$37.13 million, a PE ratio of -6.59 and a beta of 0.48. Microbix Biosystems Inc. has a 12 month low of C$0.21 and a 12 month high of C$0.34. The company has a current ratio of 5.35, a quick ratio of 5.57 and a debt-to-equity ratio of 27.03.

Microbix Biosystems (TSE:MBX – Get Free Report) last announced its quarterly earnings results on Thursday, May 14th. The company reported C($0.01) EPS for the quarter. Microbix Biosystems had a negative net margin of 38.62% and a negative return on equity of 21.02%. The firm had revenue of C$3.38 million during the quarter. On average, sell-side analysts expect that Microbix Biosystems Inc. will post 0.02 EPS for the current year.

Microbix Biosystems Company Profile

(Get Free Report)

Microbix develops proprietary biological technology solutions for human health and well-being, with about 90 skilled employees and sales growing from a base of over $1 million per month. It makes a wide range of critical biological materials for the global diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment products that support clinical lab proficiency testing, assay development and validation, or clinical lab workflows.

Further Reading

• Five stocks we like better than Microbix Biosystems
• Costco’s Strong Quarter Still Leaves Investors With a Valuation Problem
• These 3 Software Stocks Are Buying Back Shares Hand Over Fist
• Gap Inc. Cuts Sales Outlook After Q1 Miss, Shares Drop 17%
• MongoDB’s AI Advantage Is Starting to Show Up in Results

Receive News & Ratings for Microbix Biosystems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Microbix Biosystems and related companies with MarketBeat.com's FREE daily email newsletter.